Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2013 | short review | Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013

Management of immunosuppression in the treatment of chronic lymphocytic leukemia

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2013
Autoren:
MD Jutta Auberger, MD Prof. Richard Greil

Abstract

In patients with chronic lymphocytic leukemia (CLL), infections exert a substantial influence on morbidity and mortality. Hypogammaglobulinemia is one important predisposing factor for development of infections. The use of purine analogs, such as fludarabine, and monoclonal antibodies, such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis jiroveci, mycobacteria, listeria, and herpes viruses, as well as of fungal infections; these infections are mainly related to cellular immunosuppression induced by these agents. This short review focusses on risk factors, the causative spectrum of infectious complications, and possible preventive approaches in CLL patients, including antimicrobial, immunoglobulin prophylaxis, and vaccination strategies.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe